ライフサイエンスコーパス: conjugated equine estrogen

1 Studies have shown that conjugated equine estrogen 0.625 mg a day plus medroxypr

2 me inhibitors [3]) were randomly assigned to conjugated equine estrogens 0.625 mg (combined with medr

3 ized, single-blind, crossover treatment with conjugated equine estrogens 0.625 mg per os per day, ram

4 usal women randomized to treatment with oral conjugated equine estrogen (0.625 mg/d), estrogen plus p

5 Women with prior hysterectomy received oral conjugated equine estrogen (0.625 mg/day) or placebo.

6 dy of the Women's Health Initiative trial of conjugated equine estrogens (0.625 mg per day) as compar

7 s were randomly assigned to a combination of conjugated equine estrogens (0.625 mg per day) plus medr

8 rticipants were randomly assigned to receive conjugated equine estrogens (0.625 mg per day) plus medr

9 ct uterus (n=2763) were randomly assigned to conjugated equine estrogens (0.625 mg) combined with med

10 6,608 women with a uterus were randomized to conjugated equine estrogens (0.625 mg/d [estrogen]) plus

11 andomized postmenopausal women to placebo or conjugated equine estrogens (0.625 mg/d) plus medroxypro

12 Continuous therapy with conjugated equine estrogen, 0.3 mg/d, and medroxyprogest

13 ltibotanical plus dietary soy counseling; 4) conjugated equine estrogen, 0.625 mg daily, with or with

14 oxifene, 60 mg/d; raloxifene, 120 mg/d; HRT (conjugated equine estrogen, 0.625 mg/d, and medroxyproge

15 Women were randomly assigned to receive conjugated equine estrogen, 0.625 mg/d, plus medroxyprog

16 orial design to receive hormone replacement (conjugated equine estrogen, 0.625 mg/d, with or without

17 Conjugated equine estrogens, 0.625 mg, plus medroxyproge

18 Conjugated equine estrogens, 0.625 mg, plus medroxyproge

19 nts were randomly assigned to receive either conjugated equine estrogens, 0.625 mg, plus medroxyproge

20 Conjugated equine estrogens, 0.625 mg/d, plus medroxypro

21 s were randomly assigned to receive combined conjugated equine estrogens, 0.625 mg/d, plus medroxypro

22 Participants received conjugated equine estrogens, 0.625 mg/d, plus medroxypro

23 Annual smears; oral conjugated equine estrogens, 0.625 mg/d, plus medroxypro

24 Twenty-one-day treatment with conjugated equine estrogens, 1.25 mg/d, randomly crossed

25 n with prior hysterectomy were randomized to conjugated equine estrogens alone (0.625 mg/d) or placeb

26 esterone acetate for postmenopausal women or conjugated equine estrogens alone for those with prior h

27 ing statistical significance in the trial of conjugated equine estrogens alone in women with prior hy

28 cases over a mean of 7.1 years among 10 251 conjugated equine estrogens alone participants.

29 Conjugated equine estrogen and 17beta-estradiol have con

30 d 1 daily tablet containing 0.625 mg of oral conjugated equine estrogen and 2.5 mg of medroxyprogeste

31 ed coronary heart disease who received daily conjugated equine estrogen and medroxy-progesterone acet

32 Continuous low-dose HRT with conjugated equine estrogen and oral medroxyprogesterone

33 Hormone therapy with conjugated equine estrogen and progestin had no signific

34 post-hysterectomy participants in a trial of conjugated equine estrogens and 16,608 participants with

35 rmone replacement (oral dose of 0.625 mg/day conjugated equine estrogens and 2.5 mg/day medroxyproges

36 iative Hormone Therapy), treatment with oral conjugated equine estrogens and medroxyprogesterone acet

37 postmenopausal women over 60 who are taking conjugated equine estrogens and the beneficial effect of

38 for 30 months; 25 received 175 microg/day of conjugated equine estrogens, and 21 served as untreated

39 Among these women, use of conjugated equine estrogens appeared to produce elevatio

40 rgone oophorectomy and hysterectomy received conjugated equine estrogens (at least 0.625 mg per day o

41 Our finding that conjugated equine estrogen but not esterified estrogen w

42 We randomly assigned 28 women to conjugated equine estrogen (CE) 0.625 mg, simvastatin 10

43 assigned 28 healthy postmenopausal women to conjugated equine estrogens (CE) 0.625 mg/d, vitamin E 8

44 ith a uterus were randomly assigned to daily conjugated equine estrogen (CEE) 0.625 mg, plus medroxyp

45 r random assignment to hormone therapy (HT) (conjugated equine estrogen (CEE) alone or CEE plus medro

46 mly assigned to receive either 0.625 mg/d of conjugated equine estrogen (CEE) or placebo.

47 ught to test whether one month of daily oral conjugated equine estrogen (CEE) or transdermal estradio

48 506 were randomized to receive 0.625 mg/d of conjugated equine estrogen (CEE) plus 2.5 mg/d of medrox

49 fore, we assessed the long-term influence of conjugated equine estrogen (CEE) plus medroxyprogesteron

50 The 3 ERT regimes studied were: (1) oral conjugated equine estrogen (CEE), (2) oral 17-beta estra

51 tmenopausal women with prior hysterectomy to conjugated equine estrogen (CEE; 0.625 mg/d) or placebo.

52 men aged 50 to 79 years who were given daily conjugated equine estrogen (CEE; 0.625 mg; n=5310) or pl

53 Conjugated equine estrogens (CEE) (0.625 mg/d) or placeb

54 tigated associations between the use of oral conjugated equine estrogens (CEE) (0.625 mg/day) plus me

55 ind, placebo-controlled, randomized trial of conjugated equine estrogens (CEE) 0.625 mg daily plus me

56 Trial who were randomly assigned to receive conjugated equine estrogens (CEE) 0.625 mg/d; CEE and me

57 placebo-controlled hormone therapy trials of conjugated equine estrogens (CEE) among posthysterectomy

58 f coronary heart disease (CHD), whereas oral conjugated equine estrogens (CEE) did not.

59 undergone a hysterectomy were randomized to conjugated equine estrogens (CEE) or placebo and 16,608

60 itive impairment (MCI) in women treated with conjugated equine estrogens (CEE) plus medroxyprogestero

61 Conjugated equine estrogens (CEE) with or without medrox

62 lth Initiative Estrogen-Aone trial comparing conjugated equine estrogens (CEE) with placebo was stopp

63 Treatments were placebo, conjugated equine estrogens (CEE), CEE plus cyclic medro

64 Conjugated equine estrogens (CEE, 0.625 mg/d) plus medro

65 Women with an intact uterus received conjugated equine estrogens (CEE; 0.625 mg/d) plus medro

66 However, the effects of conjugated equine estrogens (CEEs) alone on mammographic

67 risk among women assigned to daily 0.625-mg conjugated equine estrogens (CEEs) compared with placebo

68 Lower-than-commonly-prescribed doses of conjugated equine estrogens (CEEs) with medroxyprogester

69 of this study was to compare the effects of conjugated equine estrogens (CEEs) with those of tamoxif

70 HT included conjugated equine estrogens (E) alone for women without

71 stricted to estrogen users, current users of conjugated equine estrogen had a higher risk than curren

72 In contrast, women currently taking conjugated equine estrogen had an elevated risk (OR, 1.6

73 Health Initiative, indicating that unopposed conjugated equine estrogen is unlikely to be cardioprote

74 BF measurements were repeated after 25 mg of conjugated equine estrogens IV.

75 findings from these trials, which used oral conjugated equine estrogens, may not be generalizable to

76 re randomly assigned to receive 0.625 mg/day conjugated equine estrogens (n = 5,076), or placebo (n =

77 randomized to receive 4 y of 0.45 mg/d oral conjugated equine estrogens (o-CEE) plus 200 mg/d micron

78 Oral conjugated equine estrogens (o-CEE), 0.45 mg/d, or trans

79 se would show cognitive benefits, while oral conjugated equine estrogens (oCEE) would show no effect,

80 mg/d) if they had a uterus (N=16 608) or to conjugated equine estrogens only if they had prior hyste

81 sturbances were randomly assigned to receive conjugated equine estrogens or placebo in a 4-week clini

82 eceived either 1 daily tablet of 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogest

83 line to estrogen plus progestin (0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogest

84 Random assignment to 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyproge

85 Participants received 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyproge

86 mly assigned to receive either 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyproge

87 Conjugated equine estrogen plus medroxyprogesterone acet

88 follow-up of 4.1 years, treatment with oral conjugated equine estrogen plus medroxyprogesterone acet

89 n which one study group received 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyproges

90 One tablet per day containing 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyproges

91 Either 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyproges

92 progestin (n = 8,240), given as 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyproge

93 f invasive breast cancer with daily 0.625-mg conjugated equine estrogens plus 2.5-mg medroxyprogester

94 lts do not support hormone therapy with oral conjugated equine estrogens plus medroxyprogesterone ace

95 and Estrogen/Progestin Replacement Study) of conjugated equine estrogens plus medroxyprogesterone fai

96 orial design to receive either 0.625 mg/d of conjugated equine estrogen (plus 2.5 mg/d of medroxyprog

97 monkeys were ovariectomized and treated with conjugated equine estrogens (Premarin) at doses that are

98 en with coronary disease and hyperlipidemia, conjugated equine estrogen produced significant improvem

99 r 3 years, the first group received ERT with conjugated equine estrogens, the second group received S

100 The active regimens were conjugated equine estrogens therapy at 0.625 mg daily, a

101 Among conjugated equine estrogen users, increasing daily dose

102 either 1 daily tablet containing 0.625 mg of conjugated equine estrogen with 2.5 mg of medroxyprogest

103 nopausal women with coronary artery disease, conjugated equine estrogen with or without continuous ad

104 e, and all-cause mortality) was reduced with conjugated equine estrogens with a hazard ratio of 0.82

105 in relation to current use of esterified or conjugated equine estrogens, with or without concomitant

106 Initiative randomized trials (1993-2004) of conjugated equine estrogens, with or without medroxyprog